



LEERINK SWANN

**Novel Cancer Therapeutics Roundtable Conference
Wednesday, May 20, 2009**

Tentative Agenda (as of 5.14.09)

The Roosevelt Hotel
45 West 45th Street (at Madison Avenue)

Phone (212) 661-9600
Fax (212) 885-6161

Time	All meetings will be held in the Grand Ballroom, Conference Level
7:30-8:00am	Conference Registration and Continental Breakfast (Ballroom Foyer, Mezzanine Level)
8:00-8:05	Welcome Remarks John Sullivan, Director of Equity Research and Healthcare Strategist, Managing Director, Leerink Swann
8:05-8:10	Oncology Overview Howard Liang, Ph.D., Analyst, Biotechnology, Leerink Swann
8:10-9:30	Expert Panel: New Developments in Solid Tumors, Focusing on GU and GI Cancers <i>Company Representatives:</i> Brian Schwartz, M.D., Chief Medical Officer, ArQule, Inc. Elan Ezickson, Chief Business Officer, AVEO Pharmaceuticals, Inc. Mitchell Gold, M.D., President and Chief Executive Officer, Dendreon Corporation Llew Keltner, M.D., Ph.D., President and Chief Executive Officer, Light Sciences Oncology David Hung, M.D., President and Chief Executive Officer, Medivation, Inc. Jerry McMahon, Ph.D., Chairman and Chief Executive Officer, Poniard Pharmaceuticals, Inc. Robert Terifay, Senior Vice President, Commerical, Regeneron Pharmaceuticals, Inc. <i>MEDACorp Opinion Leaders:</i> Howard Hochster, M.D. and Daniel Petrylak, M.D. <i>Moderator:</i> Howard Liang, Ph.D., Analyst, Biotechnology, Leerink Swann and Jess Barnes, Vice President, MEDACorp
9:30-9:45	AVEO Pharmaceuticals, Inc. Elan Ezickson, Chief Business Officer
9:45-10:00	ArQule, Inc. Paolo Pucci, Chief Executive Officer
10:00-10:15	Dendreon Corporation Mitchell Gold, M.D., President and Chief Executive Officer
10:15-10:30	Morning Break
10:30-10:45	Medivation, Inc. David Hung, M.D., President and Chief Executive Officer
10:45-11:00	PTC Therapeutics, Inc. Langdon Miller, M.D., Chief Medical Officer
11:00-11:15	Regeneron Pharmaceuticals, Inc. Murray Goldberg, Chief Financial Officer
11:15-11:30	Light Sciences Oncology Llew Keltner, M.D., Ph.D., President and Chief Executive Officer
11:30-Noon	Lunch Break (a buffet lunch is available in the Ballroom Foyer, Mezzanine Level)
Noon-1:00pm	Expert Panel: Novel Approaches to Cancer Therapy <i>Company Representatives:</i> Chiang Li, M.D., Chairman, Chief Executive and Scientific Officer, Boston Biomedical, Inc. Robert Hariri, Chief Executive Officer, Celgene Cellular Daniel Passeri, President and Chief Executive Officer, Curis, Inc. Jeffrey Tong, Ph.D., Vice President, Corporate and Product Development, Infinity Pharmaceuticals, Inc. Christian Itin, Ph.D., President and Chief Executive Officer, Micromet, Inc. Langdon Miller, M.D., Chief Medical Officer, PTC Therapeutics, Inc. <i>MEDACorp Opinion Leader:</i> William Matsui, M.D. <i>Moderator:</i> Howard Liang, Ph.D., Senior Biotechnology Analyst, Leerink Swann and Joseph Schwartz, Senior Biotechnology Analyst, Leerink Swann
1:00-1:30	Afternoon Break
1:30-1:45	Curis, Inc. Daniel Passeri, President and Chief Executive Officer
1:45-2:00	Micromet, Inc. Christian Itin, Ph.D., President and Chief Executive Officer
2:00-2:15	Poniard Pharmaceuticals, Inc. Jerry McMahon, Ph.D., Chairman and Chief Executive Officer
2:15-2:30	ARIAD Pharmaceuticals, Inc. Harvey Berger, M.D., Chairman and Chief Executive Officer
2:30-2:45	Array BioPharma, Inc. Robert Conway, Chief Executive Officer
2:45-3:00	Cephalon, Inc. Lesley Russell, MRCP, Executive Vice President and Chief Medical Officer, Worldwide Medical and Regulatory Operations
3:00-3:15	Proteolix, Inc. Craig Parker, Senior Vice President, Finance and Corporate Development and Chief Financial Officer
3:15-3:30	Seattle Genetics, Inc. Tom Reynolds, M.D., Ph.D., Chief Medical Officer
3:30-4:30	Expert Panel: New Development in Liquid Tumors <i>Company Representatives:</i> Harvey Berger, M.D., Chairman and Chief Executive Officer, ARIAD Pharmaceuticals, Inc. Kevin Koch, President and Chief Scientific Officer, Array BioPharma, Inc. Lesley Russell, MRCP, Executive Vice President and Chief Medical Officer, Worldwide Medical and Regulatory Operations, Cephalon, Inc. Craig Parker, Senior Vice President, Finance and Corporate Development and Chief Financial Officer, Proteolix, Inc. Tom Reynolds, M.D., Ph.D., Chief Medical Officer, Seattle Genetics, Inc. <i>MEDACorp Opinion Leaders:</i> Ruben Niesvizky, M.D. and Ariela Noy, M.D. <i>Moderator:</i> Howard Liang, Ph.D., Analyst, Biotechnology, Leerink Swann and Jess Barnes, Vice President, MEDACorp

*Private 1-1 meetings with MEDACorp Opinion Leaders and Company Management will be held throughout the day. You must register for these meetings at the registration desk.